Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 1001 - 1025 of 14651 in total
Ketazolam is a benzodiazepine derivative with anxiolytic, anticonvulsant, sedative and skeletal muscle relaxant activity. Ketazolam is not approved in Canada or America.
Approved
Matched Description: … Ketazolam is a benzodiazepine derivative with anxiolytic, anticonvulsant, sedative and skeletal muscle …
Matched Categories: … Benzodiazepines and benzodiazepine derivatives …
An ergot derivative that has been used as a cerebral vasodilator and in peripheral vascular disease. It has been suggested to ameliorate cognitive deficits in cerebrovascular disease.
Approved
Investigational
Matched Description: … An ergot derivative that has been used as a cerebral vasodilator and in peripheral vascular disease. …
Matched Categories: … Ergot Alkaloids and Derivatives …
Pitolisant is a selective antagonist or inverse agonist of the histamine H3 receptor used to treat type 1 or 2 narcolepsy. Narcolepsy is a chronic neurological disorder that affects 1 in 2,000 individuals and is characterized by excessive daytime sleepiness, abnormal REM sleep manifestations, sleep paralysis and hypnagogic hallucinations. About...
Approved
Investigational
Matched Description: … [L8063] Narcolepsy is a chronic neurological disorder that affects 1 in 2,000 individuals and is characterized ... [A32023] Adolescent patients with cataplexy also experienced a slight improvement in the frequency and ... treating refractory sleepiness in adolescent patients with narcolepsy, where it decreased ESS score and
Ripretinib is a kinase inhibitor used for the treatment of advanced gastrointestinal stromal tumor (GIST) that has not adequately responded to other kinase inhibitors such as sunitinib and imatinib. Ripretinib, also known as Qinlock, is manufactured by Deciphera Pharmaceuticals and was initially approved by the FDA on May 15, 2020....
Approved
Matched Description: … stromal tumor (GIST) that has not adequately responded to other kinase inhibitors such as [sunitinib] and ... Ripretinib, also known as Qinlock, is manufactured by Deciphera Pharmaceuticals and was initially approved …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Polyquaternium-10 is a quaternized hydroxyethyl cellulose and a polycationic polymer. It is commonly found in cosmetics and personal care products to mainly reduce static electricity and form films.
Approved
Matched Description: … It is commonly found in cosmetics and personal care products to mainly reduce static electricity and ... Polyquaternium-10 is a quaternized hydroxyethyl cellulose and a polycationic polymer. …
Tafamidis and tafamidis meglumine (FX-1006A) are benzoxazole derivatives developed by FoldRX. Tafamidis is structurally similar to diflusinal. Tafamidis was granted an EMA market authorisation on 16 November 2011 and FDA approval on 3 May 2019.
Approved
Investigational
Matched Description: … Tafamidis and tafamidis meglumine (FX-1006A) are benzoxazole derivatives[A27206] developed by FoldRX. ... [A189717] Tafamidis was granted an EMA market authorisation on 16 November 2011[L6247] and FDA approval …
Matched Categories: … Hormones, Hormone Substitutes, and Hormone Antagonists …
Perflutren, a diagnostic drug that is intended to be used for contrast enhancement during the indicated echocardiographic procedures, is comprised of lipid-coated microspheres filled with octafluoropropane(OFP) gas. When exposed to ultrasound waves, the microspheres resonate and "echo" strong signals back to the ultrasound machine. The difference in density between the...
Approved
Matched Description: … The difference in density between the gas-filled bubbles and the blood around them creates an increased ... When exposed to ultrasound waves, the microspheres resonate and "echo" strong signals back to the ultrasound …
Matched Categories: … Amino Acids, Peptides, and Proteins …
Cenobamate, or YKP-3089, is an antiepileptic drug developed by SK Pharmaceuticals and used to treat partial onset seizures.[A188442,L10653] The exact mechanism of action has not been described in the literature, though it positively modulates GABAA and inhibits voltage gated sodium channels. Cenobamate was granted FDA approval on 21 November 2019.
Approved
Investigational
Matched Description: … Cenobamate, or YKP-3089, is an antiepileptic drug developed by SK Pharmaceuticals and used to treat partial ... of action has not been described in the literature, though it positively modulates GABAA and
Patent blue is aniline dye and it is one of the most common dyes used. It is a sodium or calcium salt of diethylammonium hydroxide inner salt. It has the chemical designation of (4-(alpha-(p-(diethylamino)phenyl)-2,4-disulfobenzylidene)-2,5-cyclohexadiene-1-ylidene)diethylammonium hydroxide. Patent blue was developed by Guerbet and approved by Health Canada on December 31, 1979....
Approved
Matched Description: … Patent blue is aniline dye and it is one of the most common dyes used. ... Patent blue was developed by Guerbet and approved by Health Canada on December 31, 1979. …
A carbamate derivative used as an alcohol deterrent. It is a relatively nontoxic substance when administered alone, but markedly alters the intermediary metabolism of alcohol. When alcohol is ingested after administration of disulfiram, blood acetaldehyde concentrations are increased, followed by flushing, systemic vasodilation, respiratory difficulties, nausea, hypotension, and other symptoms...
Approved
Matched Description: … increased, followed by flushing, systemic vasodilation, respiratory difficulties, nausea, hypotension, and
Matched Categories: … Scabicides, Insecticides and Repellents ... Antiparasitic Products, Insecticides and Repellents …
Rimegepant is an oral antagonist of the CGRP receptor developed by Biohaven Pharmaceuticals. It received FDA approval on February 27, 2020 for the acute treatment migraine headache, and was subsequently approved by the European Commission in April 2022 for both the treatment and prevention of migraines. While several parenteral antagonists...
Approved
Investigational
Matched Description: … [L41640] While several parenteral antagonists of CGRP and its receptor have been approved for migraine ... L11028] It received FDA approval on February 27, 2020 for the acute treatment migraine headache,[L11974] and ... was subsequently approved by the European Commission in April 2022 for both the treatment and prevention …
Topiramate is a anti-epileptic drug used to manage seizures and prevent migraines. It was initially approved by the FDA in 1996. In 2004, topiramate was approved for the prevention of migraine in adults.[A188309,L10544,L43478] Since 2012, the extended-release formulation has been approved in combination with phentermine for chronic weight management therapy...
Approved
Matched Description: … Topiramate is a anti-epileptic drug used to manage seizures and prevent migraines. ... topiramate from other antiepileptic drugs are a monosaccharide chemical structure containing a sulfamate, and
Matched Categories: … Alimentary Tract and Metabolism ... phentermine and topiramate …
Approved
Experimental
Matched Categories: … Diet, Food, and Nutrition …
Hydroxyzine is a first-generation histamine H1-receptor antagonist of the dephenylmethane and piperazine classes that exhibits sedative, anxiolytic, and antiemetic properties.[A1257,A187589] It was first developed in 1955, and has since remained a relatively common treatment for allergic conditions such as pruritus, urticaria, dermatoses, and histamine-mediated pruritus. The active metabolite of hydroxyzine,...
Approved
Matched Description: … piperazine classes that exhibits sedative, anxiolytic, and antiemetic properties. ... Hydroxyzine is a first-generation histamine H1-receptor antagonist of the dephenylmethane and ... for allergic conditions such as pruritus, urticaria, dermatoses, and histamine-mediated pruritus. …
Matched Categories: … Miscellaneous Anxiolytics Sedatives and Hypnotics …
Vardenafil is a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5) and an oral therapy for the treatment of erectile dysfunction.[L45563,L45568] During sexual stimulation, nitric oxide (NO) is released from nerve endings and endothelial cells in the corpus cavernosum, activating the enzyme guanylate cyclase and increasing the...
Approved
Matched Description: … selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type 5 (PDE5) and ... cells in the corpus cavernosum, activating the enzyme guanylate cyclase and increasing the synthesis ... Compared to [sildenafil] and [tadalafil], vardenafil is a more potent inhibitor of PDE5; however, its …
Matched Categories: … Genito Urinary System and Sex Hormones …
Terbutaline was first synthesized in 1966 and described in the literature in the late 1960s and early 1970s. It is a selective beta-2 adrenergic agonist used as a bronchodilator in asthmatic patients.[A230333,L32093,L32098] Terbutaline was granted FDA approval on 25 March 1974.
Approved
Matched Description: … and early 1970s. ... Terbutaline was first synthesized in 1966[A230333] and described in the literature in the late 1960s …
Bepotastine is a non-sedating, selective antagonist of the histamine 1 (H1) receptor. Bepotastine was approved in Japan for use in the treatment of allergic rhinitis and uriticaria/puritus in July 2000 and January 2002, respectively, and is marketed by Tanabe Seiyaku Co., Ltd. under the brand name Talion. It is available...
Approved
Matched Description: … in July 2000 and January 2002, respectively, and is marketed by Tanabe Seiyaku Co., Ltd. under the brand ... It is available in oral and opthalmic dosage forms in Japan. ... The opthalmic solution is FDA approved since Sept 8, 2009 and is under the brand name Bepreve. …
Ramelteon is the first in a new class of sleep agents that selectively binds to the melatonin receptors in the suprachiasmatic nucleus (SCN). It is used for insomnia, particularly delayed sleep onset. Ramelteon has not been shown to produce dependence and has shown no potential for abuse.
Approved
Investigational
Matched Description: … Ramelteon has not been shown to produce dependence and has shown no potential for abuse. …
Matched Categories: … Hypnotics and Sedatives …
Ertapenem is a 1-β methyl-carbapenem that is structurally related to beta-lactam antibiotics. It was first authorized for use in the US in November 2001 and in Europe in April 2002. Shown to be effective against a wide range of Gram-positive and Gram-negative aerobic and anaerobic bacteria, ertapenem is used to...
Approved
Investigational
Matched Description: … [A447] Shown to be effective against a wide range of Gram-positive and Gram-negative aerobic and anaerobic ... [L14339] It was first authorized for use in the US in November 2001 and in Europe in April 2002. …
Sodium sulfide is a chemical compound with a chemical formula Na2S. Sodium sulfide is used in the pulp and paper industry, water treatment, textile industry, and various chemical manufacturing processes including the production of rubber chemicals, sulfur dyes and oil recovery. Along with its hydrate form, sodium sulfide releases hydrogen...
Approved
Matched Description: … Sodium sulfide is used in the pulp and paper industry, water treatment, textile industry, and various ... However the clinical significance and mechanism of action of sodium sulfide and replication of results ... been investigated in models of inflammation and oxidative stress. …
Sotagliflozin is a dual inhibitor of SGLT1 and SGLT2, the first of its kind, which is approved for use in the EU, in combination with insulin, to improve glycemic control in patients with type 1 diabetes mellitus (T1DM) and a BMI ≥27 kg/m2. Its potency in inhibiting SGLT2 is similar...
Approved
Investigational
Matched Description: … Sotagliflozin is a dual inhibitor of SGLT1 and SGLT2, the first of its kind,[A244499] which is approved ... combination with insulin, to improve glycemic control in patients with type 1 diabetes mellitus (T1DM) and ... Its potency in inhibiting SGLT2 is similar to that of other SGLT2 inhibitors, such as [canagliflozin] and
Matched Categories: … Alimentary Tract and Metabolism …
Iron deficiency is an extremely common condition and is the most frequent cause of anemia worldwide. Iron deficiency results when iron intake, iron stores, and loss of iron from the body do not adequately support production of erythrocytes, also known as red blood cells. Though it is generally considered non...
Approved
Matched Description: … This drug is a complex of iron (III) hydroxide and derisomaltose. ... Iron deficiency is an extremely common condition and is the most frequent cause of anemia worldwide. ... Iron deficiency results when iron intake, iron stores, and loss of iron from the body do not adequately …
Pentastarch is an artificial colloid (hydroxyethyl starch derivative). Pentastarch is characterized by presenting five hydroxyethyl groups, which signifies an approximate 50% hydroxyethylation. It is sold under the name Pentaspan by Bristol-Myers Squibb and is used for fluid resuscitation. When administered, pentastarch remains mainly in the circulatory system and hence, it...
Approved
Investigational
Matched Description: … It is sold under the name Pentaspan by Bristol-Myers Squibb and is used for fluid resuscitation. ... When administered, pentastarch remains mainly in the circulatory system and hence, it is considered a …
Micronomicin is an aminoglycoside antibiotic which is marketed in Japan, and sold under the brand names Sagamicin and Luxomicina.
Approved
Matched Description: … Sagamicin and Luxomicina. ... Micronomicin is an aminoglycoside antibiotic which is marketed in Japan, and sold under the brand names …
Approved
Investigational
Nutraceutical
Displaying drugs 1001 - 1025 of 14651 in total